Meet the Fischells. Four members of one family are collectively responsible for filing more than 200 patents in the medical device field, founding more than 14 device companies, including NeuroPace, Neuralieve, Angel Medical, Svelte Medical and GlucoTec, and inventing the world's most widely-used implantable medical device in the history of the industry, the stent design sold by Johnson & Johnson as the Bx Velocity. START-UP interviews the four Fischells to learn the secrets of their success.
By Mary Stuart
Meet the Fischells. Four members of the immediate family are collectively responsible for filing more than 200 patents in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.